Summit Therapeutics Co-CEOs Bought $100M in June. AstraZeneca Paid 40% More.

Two Co-CEOs put in $100 million. Then AstraZeneca showed up.

Two Summit Therapeutics Co-CEOs each bought about $50 million of their own stock in June. On September 28, AstraZeneca invested $2.0 billion at an effective $18.36 a share, about 40% above the $13.12 the insiders paid.

Robert Duggan and Mahkam Zanganeh run Summit $SMMT, the developer of the cancer drug ivonescimab. Their June purchases and AstraZeneca’s September investment sit in two different SEC filings, three months apart. Put together, they tell a story neither filing tells alone.

What the insiders did in June

The Company Dossier shows six Form 4 transactions for Summit, all of them buys, netting +$103.6 million. Duggan and Zanganeh each bought $50.0 million on June 11, and Zanganeh added another $1.5 million on June 3. News coverage of the filings put the price at $13.12 a share, or about 3.81 million shares per Co-CEO.

Duggan’s filing was coded as an open-market purchase. The stock was trading near its 52-week low at the time, according to Investing.com. There is no insider selling in the file, and the Dossier’s Form 144 check shows no planned selling in the current period or the trailing 90 days.

What AstraZeneca did in September

In an 8-K, Summit disclosed that AstraZeneca Holdings B.V. bought 108,955.3686 shares of new Class A Convertible Preferred Stock at $18,356.14 each, for $2.0 billion. Each preferred share converts into 1,000 common shares, which works out to $18.36 per common share. Per the company’s press release, that price is the five-day VWAP plus 10%. The private placement closed on September 28.

The deal also includes a clinical collaboration to test ivonescimab with AstraZeneca’s antibody-drug conjugate sonesitatug vedotin in gastrointestinal cancers. A separate, non-binding memorandum covers combinations with other AstraZeneca cancer medicines, with no milestone, royalty or profit-sharing fees. Benzinga reported the stake at roughly 12% of Summit on a fully diluted basis.

Did the Co-CEOs know?

Not on the evidence. Open-market purchases are supposed to be made without material inside information, and nothing in the filings says otherwise. What the Form 4s did show is who was willing to put $100 million behind the drug at $13.12, at a moment when the stock was near its lows.

This is also not a takeover. AstraZeneca bought convertible preferred stock and signed a collaboration. It did not buy Summit. Reading it as an acquisition, or reading the June buys as a hint that a deal was coming, both overreach.

The bigger pattern: what the Dossier adds

The Dossier’s Company scores put the story in context. Summit scores 10.0 out of 10 on Governance (top 11% of companies scored) and 6.6 on Insider Conviction (top 34%). Earnings Quality is 0.2 out of 10 (bottom 2%), Financial Strength is 3.3, and the overall score is 26.2 out of 50, labeled Average.

That is what you would expect from a clinical-stage biotech that spends heavily and has flagged going concern language in four filings. It is also why the $2.0 billion matters: it is capital, and it is a large outside vote on the pipeline. It is not proof the drug works.

One insider buy is noise. Two Co-CEOs buying on the same day, with nobody selling, is a pattern worth reading.

The lesson: read the whole filing, not the headline

The September headline was AstraZeneca. The earlier tell was sitting in two Form 4s from June. NexusAlert summarizes the 8-K the day it lands and puts the insider, ownership and score history for the same company on one Dossier page, so you can see both halves without digging through EDGAR.

Create a free NexusAlert account

Sources

• AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics (Business Wire, Sep 28, 2026)
• Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab (Benzinga)
• Summit Therapeutics co-CEO Robert Duggan buys $49.9M in stock (Investing.com)
• Summit Therapeutics co-CEO Zanganeh acquires $49.98M in shares (Investing.com)
• SMMT Form 4: Robert Duggan buys 3.81M shares in open market (Stock Titan)
• Summit Therapeutics Shares Rebound After Co-CEO’s $50M Stock Purchase (GuruFocus)
• NexusAlert Company Dossier for SMMT, Sep 29, 2026